Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Immutep Targets New Cancer Trials After Manufacturing Differences Identified in Failed Study

Immutep Limited (IMM) · Health care

IMM: $0.023 -4.17% · MC: $35M

Immutep says it has identified structural differences between the larger-scale efti used in discontinued TACTI-004 and the smaller-scale product used in earlier successful studies, and has contracted a new smaller-scale manufacturing run. The company intends to focus future registration-directed efti development on head and neck cancer and soft tissue sarcoma, with trial starts targeted for the second half of 2027; its cash runway is expected to extend well into the first half of 2028. Its soft tissue sarcoma trial met its primary endpoint, while IMP761 is now a co-priority alongside efti.

Source announcements: 2026-10-29 08:04 to 2026-10-29 08:04 Sydney time
Story updated 2026-10-29 11:39 Sydney time
SourcesImmutep Quarterly Activities Report and Appendix 4C
Comments